Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Agile Therapeutics Inc.

    NASDAQ: AGRX · Real-Time Price · USD
    1.51
    0.05 (3.42%)
    At close: Aug 22, 2024, 9:58 PM

    Agile Therapeutics Statistics

    Share Statistics

    Agile Therapeutics has 6.9M shares outstanding. The number of shares has increased by 0.7% in one year.

    Shares Outstanding

    n/a
    		 6.9M

    Shares Change (YoY)

    n/a
    		 0.7%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 0%

    Shares Floating

    n/a
    		 5.14M

    Failed to Deliver (FTD) Shares

    n/a
    		 16

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 11.74K, so 0.17% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 11.74K

    Short % of Shares Out

    n/a
    		 0.17%

    Short % of Float

    n/a
    		 0.17%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.29 and the forward PE ratio is null. Agile Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.29

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0.21

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 -0.26

    P/FCF Ratio

    n/a
    		 -0.44

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Agile Therapeutics has an Enterprise Value (EV) of 3.82M.

    EV / Sales

    n/a
    		 0.19

    EV / EBITDA

    n/a
    		 -0.19

    EV / EBIT

    n/a
    		 -0.4

    EV / FCF

    n/a
    		 -0.4

    Financial Position

    The company has a current ratio of 0.46, with a Debt / Equity ratio of -0.1.

    Current Ratio

    n/a
    		 0.46

    Quick Ratio

    n/a
    		 0.33

    Debt / Equity

    n/a
    		 -0.1

    Debt / EBITDA

    n/a
    		 -0.11

    Debt / FCF

    n/a
    		 -0.23

    Interest Coverage

    n/a
    		 -14.01

    Financial Efficiency

    Return on Equity is 88.64% and Return on Invested Capital is 149.43%.

    Return on Equity

    n/a
    		 88.64%

    Return on Assets

    n/a
    		 -141.05%

    Return on Invested Capital

    n/a
    		 149.43%

    Revenue Per Employee

    n/a
    		 $1,031,210.53

    Profits Per Employee

    n/a
    		 $-761,315.79

    Employee Count

    n/a
    		 19

    Asset Turnover

    n/a
    		 1.91

    Inventory Turnover

    n/a
    		 3.28

    Taxes

    Income Tax

    n/a
    		 1.42M

    Effective Tax Rate

    n/a
    		 -9.81%

    Stock Price Statistics

    The stock price has increased by 277.22% in the last 52 weeks. The beta is 1.58, so Agile Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.58

    52-Week Price Change

    n/a
    		 277.22%

    50-Day Moving Average

    n/a
    		 1.29

    200-Day Moving Average

    n/a
    		 1.14

    Relative Strength Index (RSI)

    n/a
    		 82.85

    Average Volume (20 Days)

    n/a
    		 143,293

    Income Statement

    In the last 12 months, Agile Therapeutics had revenue of 19.59M and earned -14.46M in profits. Earnings per share was -6.71.

    Revenue

    n/a
    		 19.59M

    Gross Profit

    n/a
    		 10.62M

    Operating Income

    n/a
    		 -19.88M

    Net Income

    n/a
    		 -14.46M

    EBITDA

    n/a
    		 -19.88M

    EBIT

    n/a
    		 -13.05M

    Earnings Per Share (EPS)

    n/a
    		 -6.71
    Full Income Statement

    Balance Sheet

    The company has 2.56M in cash and 2.17M in debt, giving a net cash position of 385K.

    Cash & Cash Equivalents

    n/a
    		 2.56M

    Total Debt

    n/a
    		 2.17M

    Net Cash

    n/a
    		 385K

    Retained Earnings

    n/a
    		 -423.17M

    Total Assets

    n/a
    		 14.96M

    Working Capital

    n/a
    		 -11.79M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -9.58M and capital expenditures 0, giving a free cash flow of -9.58M.

    Operating Cash Flow

    n/a
    		 -9.58M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -9.58M

    FCF Per Share

    n/a
    		 -4.44
    Full Cash Flow Statement

    Margins

    Gross margin is 54.18%, with operating and profit margins of -101.49% and -73.83%.

    Gross Margin

    n/a
    		 54.18%

    Operating Margin

    n/a
    		 -101.49%

    Pretax Margin

    n/a
    		 -73.83%

    Profit Margin

    n/a
    		 -73.83%

    EBITDA Margin

    n/a
    		 -101.49%

    EBIT Margin

    n/a
    		 -101.49%

    FCF Margin

    n/a
    		 -48.88%

    Dividends & Yields

    AGRX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -343.94%

    FCF Yield

    n/a
    		 -227.72%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for AGRX.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Apr 11, 2023. It was a backward split with a ratio of 1:50.

    Last Split Date

    n/a
    		 Apr 11, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:50

    Scores

    Altman Z-Score

    n/a
    		 -42.12

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist